EYEN Insider Trading
Insider Ownership Percentage: 7.10%
Insider Buying (Last 12 Months): $1,042,540.00
Insider Selling (Last 12 Months): $0.00
Eyenovia Share Price & Price History
Current Price: $1.13
Price Change: ▲ Price Increase of +0.025 (2.27%)
As of 04/1/2025 03:19 PM ET
Eyenovia Insider Trading History
Eyenovia Institutional Trading History
Data available starting January 2016
Eyenovia, Inc., an ophthalmic technology company, engages in the development of therapeutics based on its proprietary microdose array print platform technology. The company's product candidates include MicroPine, which is in Phase III clinical development program with indications for pediatric myopia progression (near-sightedness); MicroLine, which is in Phase III clinical development program with indications for the improvement in near vision in people with presbyopia; and Mydcombi, which is in Phase III clinical development program with indications for pharmaceutical mydriasis. It has a license agreement with Bausch Health Ireland Limited to develop and commercialize MicroPine in the United States and Canada; a license agreement with Arctic Vision (Hong Kong) Limited to develop and commercialize MicroPine, MicroLine, and Mydcombi in China and South Korea; and Senju Pharmaceutical Co., Ltd. to develop and commercialize MicroPine, MicroLine, and Mydcombi. The company was formerly known as PGP Holdings V, Inc. and changed its name to Eyenovia, Inc. in May 2014. Eyenovia, Inc. was incorporated in 2014 and is based in New York, New York.
Read More on Eyenovia
Volume
23,576 shs
Average Volume
150,240 shs
Market Capitalization
$1.57 million
P/E Ratio
N/A
Dividend Yield
N/A
Beta
1.29
Who are the company insiders with the largest holdings of Eyenovia?
Eyenovia's top insider shareholders include:
- Stuart M Grant (Major Shareholder)
- Tsontcho Ianchulev (Director)
- Michael M Rowe (CEO)
- Charles E Iv Mather (Director)
- Ellen R Strahlman (Director)
- John P Gandolfo (CFO)
- Bren Kern (COO)
Learn More about top insider investors at Eyenovia.